

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/50</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/66932</b> <b>(43) International Publication Date:</b> 29 December 1999 (29.12.99)
<b>(21) International Application Number:</b> PCT/FI99/00449 <b>(22) International Filing Date:</b> 26 May 1999 (26.05.99) <b>(30) Priority Data:</b> 09/099,945 19 June 1998 (19.06.98) US <b>(71) Applicant (for all designated States except US):</b> ORION CORPORATION [FI/FI]; Orionintie 1, FIN-02200 Espoo (FI). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HAIKALA, Heimo [FI/FI]; Seilimäki 18 A 4, FIN-02180 Espoo (FI). POLLESELLO, Piero [IT/FI]; Mariavägen 1 A, FIN-02700 Grankulla (FI). KAIVOLA, Juha [FI/FI]; Otavantie 4 A 11, FIN-00200 Helsinki (FI). LEVIJOKI, Jouko [FI/FI]; Airotie 5 A, FIN-00830 Helsinki (FI). <b>(74) Agent:</b> ORION CORPORATION; Orion Pharma, Industrial Property Rights, P.O. Box 65, FIN-02101 Espoo (FI).		<b>(81) Designated States:</b> AE, AU, BA, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, YU, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> NEW USE OF A PYRIDAZINONE DERIVATIVE  <b>(57) Abstract</b>  A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure or a method of increasing calcium sensitivity of contractile proteins of cardiac muscle comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## NEW USE OF A PYRIDAZINONE DERIVATIVE

The invention relates to a method of increasing calcium sensitivity of contractile proteins in the cardiac muscle and to a method for treating neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure, comprising administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide.

Racemic N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) has been described earlier as a hypotensive agent (US 3,746,712) and as a cardiotonic agent having inotropic activity (US 4,397,854). It has been reported that the inotropic action of racemic N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide is based on phosphodiesterase III (PDE III) enzyme inhibition (Ishimori t. et al., *Arzneim.-Forsch.* (1994), 44(5), 583-8). The compound (I) has an asymmetric carbon atom and may therefore exist in two stereoisomeric forms. The (R)- and (S)- enantiomers of (I) have been earlier described in Japanese patent application no. (Heisei) JP 3163050. However, biological activity data for the enantiomers has not been described.

At the moment series of inotropic compounds, e.g. milrinone, the mechanism of which is based on PDE III inhibition are in clinical trials for the treatment of heart failure. These compounds increase the contractility of the cardiac muscle by increasing the calcium current into the cardiac muscle and produce vasodilatation. The contraction in cardiac muscle is triggered by the binding of calcium to troponin in the thin filament of contractile proteins. However, it is possible that the long-term application of PDE III inhibitors leads to calcium overload in the cardiac muscle which can trigger arrhythmias. Therefore, the main mechanism to increase cardiac contractility should be a mechanism which does not produce calcium overload. The enhancement of the turnover of intracellular calcium released from sarcoplasmic reticulum and the increase of calcium sensitivity of contractile proteins are such mechanisms which do not induce calcium overload.

When a patient has harmful alterations in the cardiac function, the contractility of the cardiac muscle can still be maintained through neurohumoral activation in the body, which increases the intake of calcium in the cardiac muscle. In this situation the calcium overload can trigger arrhythmias, and prolonged neurohumoral activation will accelerate the development of heart failure. Neurohumoral imbalance can be indicated, for example, by altered renin and noradrenaline concentrations in a patient's plasma.

PDE III inhibitors can not be used chronically in the treatment of neurohumoral imbalance because they further increase the intake of calcium into the cardiac muscle. However, the use of a calcium sensitizer can sufficiently increase the contractility already in normal and decreased calcium concentrations which would reduce the need of neurohumoral activation and thereby prevent the development of heart failure.

It has been now discovered that the (R)-enantiomer of N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide has a calcium sensitizing effect on the thin filament of contractile proteins and this is its main mechanism to increase cardiac contractility. This was unexpected since the mechanism of racemic compound (I) was reported to be PDE III inhibition. Thus, being a calcium sensitizer the (R)-enantiomer of N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide has a utility in the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure.

The present invention relates to a method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering, e.g. orally or parenterally in a solid or liquid dosage form, an effective amount of (R)-enantiomer of compound (I) to a patient in need of such treatment.

The present invention also relates to a method of increasing calcium sensitivity of contractile proteins by administering an effective amount of (R)-enantiomer of compound (I) to a patient in need of such treatment.

The present invention further relates to a use of (R)-enantiomer of compound (I) in the manufacture of a medicament for use in the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure.

The present invention further relates to a use of (R)-enantiomer of compound (I) in the manufacture of a medicament for increasing calcium sensitivity of contractile proteins.

The pharmaceutically active compound according to this invention is formulated into dosage forms using the principles known in the art. It is given to a patient as such or in combination with suitable pharmaceutical excipients in the form of tablets, dragees, capsules, suppositories, emulsions, suspensions or solutions. The composition according to the invention contains a therapeutically effective amount of the pharmaceutically active compound of the invention. The content of the active compound is in the composition from about 0.5 to 100 % per weight.

In the claimed method the compound of the invention may be administered to man in oral doses ranging from about 0.1 to 500 mg, preferably 0.5 to 10 mg, per day. Choosing suitable ingredients for the composition is a routine for those of ordinary skill in the art. It is evident that suitable carriers, solvents, gel forming ingredients, dispersion  
5 forming ingredients, antioxidants, colours, sweeteners, wetting compounds and other ingredients normally used in this field of technology may be also used.

The following example will further illustrate the invention.

EXAMPLE 1. Preparation of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide

10 (R)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (30,0 g) and acetonitrile (600 mL) were mixed and the mixture was refluxed until the starting material dissolves. Acetic anhydride (30,0 mL) was added to the refluxing mixture. After 10 min the solution was allowed to cool to room temperature. The product was filtered, washed with acetonitrile and dried. Yield 30,8 g, m.p. 230-232 °C, <sup>1</sup>H-NMR  
15 (DMSO-d<sub>6</sub>, 400MHz) 1.06 (d, 3H, J = 7.3 Hz), 2.06 (s, 3H), 2.22 (d, 1H, J = 16.6 Hz), 2,67 (dd, 1H, J = 16.6 Hz, 6.8 Hz), 3.35 (m, 1H), 7.63 (d, 2H, J = 8.8 Hz), 7.72 (d, 2H, J = 8.8 Hz), 10.09 (s, 1H), 10.88 (s, 1H). [α]<sub>D</sub><sup>20</sup> = -466° (c = 2 mg/ml, DMF).

The usefulness of the compound of the invention is demonstrated by the following experiments. Compound A is (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide.  
20

#### Calcium sensitizing effect in skinned cardiac fiber

Left ventricular papillary muscle of the guinea-pig was dissected and rinsed in ice-cold Tyrode solution. Thereafter the papillary muscle was immersed into a solution containing (mM): Potassium acetate 74.7, EGTA 10, MgSO<sub>4</sub> 5.4, ATP-Na<sub>2</sub> 4, DTE 1,  
25 MOPS 20, pH 7.0 (by 1 M KOH). Subsequently, the papillary muscle was sonicated at 10 Watt for 60 sec in this ice-cold solution. The distance between ultrasound probe and the papillary muscle was 10 mm. The fibers (< 200 μm in diameter) were dissected from surface of sonicated papillary muscles. Moreover, the sonicated and dissected fibers were kept for 30 min in a "skinning" solution (ice-cold) containing saponin (250  
30 μg/ml) in addition to the other constituents. Continuous magnetic stirring was used during this treatment.

The fibers which were further dissected (< 100 μm in diameter) were then mounted horizontally with a glue (cellulose acetate in acetone) between a steel-rod extension of isometric force transducer (AME-801 strain gauge, Horten Electronics,

Norway) and a glass rod attached to a micro-manipulator. The force transducer was connected to an amplifier. The fibers were kept in the "relaxing" solution containing (mM): imidazole 30, ATP-Na<sub>2</sub> 10, NaN<sub>3</sub> 5, EGTA 5, MgCl<sub>2</sub> 12.5, and 350 U creatinkinase. The temperature of the solution was 22°C and the pH was set to 6.7 by 1 M KOH. The ionic strength was adjusted with 1 M KCl to correspond that of the "activating" solution. The composition of the "activating" solution was the same as that of the "relaxing" solution except that it contained also CaCl<sub>2</sub>. The fibers were induced to contract in desired free pCas (-log[Ca<sup>2+</sup>]) which were obtained by properly mixing of the "relaxing" and "activating" solutions. Tension produced by a fiber at pCa 4.8 was taken as maximum response. At the beginning of the experiment the fiber was stretched as described above.

The calcium sensitizing effects of Compound A and milrinone are shown in Table 1.

TABLE 1. Calcium sensitizing effect in skinned fiber at pCa 5.6

		Change in force / % of control
Compound A	0.3 $\mu$ M	+ 26 $\pm$ 6 (n = 7)
	3 $\mu$ M	+ 109 $\pm$ 35 (n = 7)
Milrinone		Ineffective

#### Positive inotropic effect in paced cardiac muscle

Four weeks old guinea-pigs weighing about 350 g were used. In the experiments the right ventricular papillary muscle of the heart was mounted for measurement of isometric tension in organ bath containing modified Tyrode solution (37°C) bubbled with 95 % O<sub>2</sub>, 5 % CO<sub>2</sub>. The composition of the modified Tyrode solution was (mM): NaCl 135; MgCl<sub>2</sub>·6H<sub>2</sub>O 1; KCl 5; CaCl<sub>2</sub>·2H<sub>2</sub>O 2; NaHCO<sub>3</sub> 15; Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O 1; glucose 10; pH 7.3 - 7.4. The volume of the open horizontal chamber was 1 ml and flow rate of the superfusion solution running through the chamber was 5 ml/min. Papillary muscle (< 1 mm in diameter) was stretched horizontally between force-displacement transducer (FT 0.3 C) and a needle fixed to the bottom of the chamber. An initial stretching tension of 300 mg was applied to the muscle which was electrically

stimulated (Stimulator model SEC 48 F, Grass Instruments) via platinum field electrodes at 1 Hz with rectangular pulses (duration 4 ms). The stimulation occurred at twice threshold voltage in order to achieve simultaneous activation of all myocytes in the capillary muscle. A force-displacement transducer was connected to a polygraph  
5 D.C. driver amplifier (model 7 DA, Grass Instruments) and a programmable scanner (model SI 5010, Tetronix). The amplified signal was digitized with 1 kHz frequency by a programmable digitizer (model 390 A, Sony Tetronix).

The inotropic effects of Compound A and milrinone are shown in Table 2.

10 TABLE 2. Positive inotropic effect in guinea-pig papillary muscle

	EC <sub>50</sub> / $\mu$ M
Compound A	0.1
Milrinone	2

## CLAIMS

1.        Use of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide  
in the manufacture of a medicament for use in the treatment of neurohumoral  
5        imbalance caused by alterations of cardiac function to prevent the development  
of heart failure.
2.        Use of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide  
in the manufacture of a medicament for increasing calcium sensitivity of  
contractile proteins of cardiac muscle.
- 10       3.        A method for the treatment of neurohumoral imbalance caused by  
alterations of cardiac function to prevent the development of heart failure by  
administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-  
pyridazinyl)phenyl]-acetamide to a mammal in need of such treatment.
- 15       4.        A method of increasing calcium sensitivity of contractile proteins of  
cardiac muscle by administering an effective amount of (R)-N-[4-(1,4,5,6-  
tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide to a patient in need of such  
treatment.



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/FI 99/00449

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 397 854 A (SIRCAR ILA) 9 August 1983 (1983-08-09) column 3, line 38-41 column 4, line 32 -column 6, line 34; claims 1-4 abstract	1-4
X	JP 58 008015 A (MITSUBISHI KASEI KOGYO KK) 18 January 1983 (1983-01-18) the whole document	1-4



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

18 October 1999

Date of mailing of the international search report

03/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3015

Authorized officer

A. Jakobs

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/FI 99/00449

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEKI, TOSHIMI ET AL: "Studies on agents with vasodilator and .beta.-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665" CHEM. PHARM. BULL. (1998), 46(1), 84-96 , XP002119278 figure 2	1-4
X	ROBERTSON, DAVID W. ET AL: "Imidazole-pyridine bioisosterism: comparison of the inotropic activities of pyridine- and imidazole-substituted 6-phenyldihydropyridazinone cardiotonics" J. MED. CHEM. (1988), 31(2), 461-5 , XP002119279 abstract; figure 1; table 1 page 463, column 1, paragraph 2 -page 464, column 1, paragraph 3	1-4
X	ROBERTSON, DAVID W. ET AL: "Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one" J. MED. CHEM. (1986), 29(10), 1832-40 , XP002119280 page 1833, column 2, paragraph 2 -page 1834, column 1, paragraph 2; figure 1; tables 2,3 page 1838, column 1, paragraph 2	1-4
X	MOHAN, C. G. ET AL: "Electric field mapping and structure-activity relationships for some dihydropyridazinone cardiotonics" THEOCHEM (1995), 332(1-2), 171-6 , XP002119281 abstract; figures 1,4; table 1	1-4
X	COATES, WILLIAM J. ET AL: "1,4-Bis(3-oxo-2,3-dihydropyridazin-6-yl)b enzene analogs: potent phosphodiesterase inhibitors and inodilators" J. MED. CHEM. (1990), 33(6), 1735-41 , XP002119282 see scheme 2 abstract; table 1	1-4

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/FI 99/00449

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SIRCAR, I. ET AL: "Cardiotonic agents. 10. Cardiovascular evaluation of dihydropyridazinone ring-opened analogs of imazodan"</p> <p>EUR. J. MED. CHEM. (1989), 24(4), 349-55 , XP002119283</p> <p>abstract; tables 3,4</p> <p style="text-align: center;">----</p>	1-4
X	<p>BAKEWELL, S. J. ET AL: "Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indeno[1,2-c]pyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tetrahydrobenzo[h]cinolin-3(2H)-ones"</p> <p>EUR. J. MED. CHEM. (1990), 25(9), 765-74 , XP002119284</p> <p>abstract; table 1</p> <p>page 770, column 1, paragraph 2</p> <p style="text-align: center;">-----</p>	1-4

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/FI 99/00449

## B x I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
See FURTHER INFORMATION SHEET PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

## Regarding Claims 1-4:

N-'4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenylacetamide has no asymmetric carbon atom or optical isomers and therefore the (R) or (S) isomers of this compound do not exist.

N-'4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenylacetamide as of example 1 exists as (R) and (S) isomers, the asymmetric carbon being carbon numbered 4 in the pyridazinone ring.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/FI 99/00449

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4397854	A	09-08-1983	US 4404203 A	13-09-1983
JP 58008015	A	18-01-1983	NONE	